SCHEDULE 13D/A: Perceptive Advisors' Director Michael Altman to Depart Nautilus Biotechnology Board

Perceptive Advisors, a significant shareholder in Nautilus Biotechnology, announced that its Managing Director, Michael Altman, will not seek re-election to the company's board of directors at the upcoming 2025 Annual Meeting.

Summary

• This is an Amendment No. 3 to a Schedule 13D filing by Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. regarding their beneficial ownership in Nautilus Biotechnology, Inc.
• Perceptive Advisors LLC and Joseph Edelman collectively beneficially own 12,594,211 shares of Common Stock, representing 10% of the class.
• Perceptive Life Sciences Master Fund, Ltd. beneficially owns 12,428,351 shares, representing 9.9% of the class.
• The primary purpose of this amendment is to disclose that Michael Altman, a Managing Director of Perceptive Advisors and a current board member of Nautilus Biotechnology since June 2021, will not stand for re-election at the Issuer's 2025 Annual Meeting of Stockholders.
• Mr. Altman will continue to serve on the Board until the conclusion of the 2025 Annual Meeting.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of a change in board composition and beneficial ownership update. It contains no positive or negative financial or operational news about the company itself, nor does it provide a reason for the director's departure that would imply sentiment.

Risks

• The departure of a director, particularly one representing a significant shareholder, could potentially lead to a loss of institutional knowledge or a shift in strategic alignment, although the filing does not elaborate on such risks.

Future Outlook

The document only states that Mr. Altman will remain on the board until the 2025 Annual Meeting. No broader future outlook for the company is provided.

Industry Context

This filing is specific to a change in board representation for Nautilus Biotechnology, a company in the biotechnology sector. The departure of a director from a significant investment firm like Perceptive Advisors could be a routine governance matter or signal a shift in the investor's engagement strategy, but the document provides no further context.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Change in board composition, specifically the departure of a director representing a significant institutional investor, which could influence future strategic direction or oversight, though the filing provides no specific impact details.

Next Steps

• Michael Altman will remain a member of the Board until the conclusion of the Issuer's 2025 Annual Meeting of Stockholders.

Key Dates

Recommendation

Keywords

Nautilus Biotechnology, Perceptive Advisors, Schedule 13D, Beneficial Ownership, Board of Directors, Director Departure, SEC Filing, Biotechnology, Investment Fund, Corporate Governance